Intuitive Surgical, Inc. (ISRG) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong growth in procedure volumes and successful adoption of the da Vinci 5 system, indicating positive market reception. Despite challenges in the bariatric and China markets, guidance updates reflect strategic adaptability. The Q&A section provides additional insights into growth areas like alternative care sites and new platforms, supporting a positive outlook. However, management's lack of clarity on certain issues tempers the sentiment slightly. Overall, the combination of strong financial performance, strategic initiatives, and positive guidance adjustments suggests a positive stock price movement.
Key Financial Performance
Worldwide procedure growth 20% year-over-year increase, driven by a 19% increase in da Vinci procedures and a 52% increase in Ion procedures. Reasons include strength in benign general surgery in the U.S. and growth in general surgery and gynecology internationally.
System utilization 4% growth for da Vinci multiport platforms, 35% for SP, and 14% for Ion. This reflects healthy procedure demand and increased adoption of da Vinci 5 systems.
Revenue $2.5 billion, a 23% year-over-year increase. Growth was driven by the broad launch of da Vinci 5 and expanded adoption of Ion and SP platforms.
Pro forma operating margin 39%, reflecting strong financial performance and operating discipline.
Pro forma earnings per share $2.40, a 30% year-over-year increase, driven by revenue growth and operational efficiency.
Installed base of da Vinci systems Increased by 13% to almost 10,800 systems. Growth reflects strong demand for da Vinci 5 systems.
Installed base of Ion systems Increased by 30% to approximately 950 systems, reflecting robust growth in Ion platform adoption.
U.S. procedure growth 18% year-over-year, with 16% growth in da Vinci procedures and 48% growth in Ion procedures. Growth reflects strong demand for da Vinci 5 and Ion systems.
Outside U.S. (OUS) procedure growth 25% year-over-year, driven by 24% growth in da Vinci procedures and a quadrupling of Ion procedures. Growth was supported by strong results in India, Canada, Korea, Taiwan, and Brazil.
Recurring revenue 21% year-over-year growth, accounting for 85% of total revenue. Growth reflects increased procedure volumes and system utilization.
Gross margin 68%, down from 69.1% last year. Decline reflects higher tariffs, facility costs, and a greater mix of lower-margin da Vinci 5 and Ion revenue.
Pro forma net income $867 million, a 30% year-over-year increase, driven by revenue growth and operational efficiency.
Free cash flow $736 million, reflecting strong operational performance and cash generation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
da Vinci 5: Expanded globally with strong domestic demand for system upgrades and dual consoles. First systems placed in Japan and Europe. FDA 510(k) clearance for software updates including Network Central Configuration Management, Force Gauge, and Focus Mode.
Ion platform: Procedures grew 52% to nearly 38,000. FDA clearance for software improving workflow and imaging options, including real-time AI for precise airway navigation.
SP platform: Procedures increased 91%, driven by growth in Korea and early progress in other international markets. Initial domestic use of SP stapler in colorectal and thoracic procedures.
International Expansion: First da Vinci 5 systems placed in Japan and Europe. Strong growth in India, Canada, Korea, Taiwan, and Brazil. Challenges in Japan, U.K., and China due to government budget constraints and competitive markets.
U.S. Market: Increased adoption of da Vinci 5 with higher utilization rates. 18 of the largest 20 IDNs in the U.S. now have at least one da Vinci 5 system.
System Utilization: Utilization grew 4% for da Vinci multiport platforms, 35% for SP, and 14% for Ion. da Vinci 5 utilization outpacing Xi.
Capital Placements: 427 da Vinci systems placed, including 240 da Vinci 5 systems. 50 Ion systems placed. Increased trade-in transactions for da Vinci 5 upgrades.
Recurring Revenue: Accounted for 85% of total revenue, with 20% growth in instrument and accessory revenue.
Focus on Innovation: FDA clearance for advanced features like Sensitive Firefly and control algorithms for SP stapler. Continued investment in AI and digital tools for real-time insights.
Customer Alignment: Engagement with customers to improve patient outcomes and operational efficiency. Focus on Quintuple Aim and fleet standardization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The company faces ongoing regulatory challenges, including the need for FDA clearances for new features and procedures, such as nipple-sparing mastectomy and other general surgery procedures. These regulatory hurdles could delay product launches and impact market adoption.
International Market Dynamics: Challenges in international markets include government budget constraints in Japan and the U.K., as well as a constrained and competitive marketplace in China. These factors could limit growth opportunities and system placements in these regions.
Supply Chain and Manufacturing Optimization: The company is focused on building industrial scale and manufacturing optimization, but any disruptions or inefficiencies in these areas could impact product availability and financial performance.
Economic and Budgetary Constraints: Economic constraints, such as government budget challenges in key markets like Japan and the U.K., could limit the adoption of the company's systems and impact revenue growth.
Competitive Pressures: The constrained and competitive marketplace in China poses a risk to the company's market share and growth in that region.
Technological Adoption and Training: The adoption of new technologies like da Vinci 5 and Ion requires significant training and customer support. Delays or challenges in these areas could impact utilization rates and customer satisfaction.
Tariff and Cost Pressures: The company faces tariff impacts and higher facility costs, which could affect gross margins and overall profitability.
Customer Budget Shifts: Some customers are shifting budgets to upgrades, which could impact the sales of new systems and alter revenue streams.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
da Vinci procedure growth: Updated full year 2025 da Vinci procedure growth guidance to be within a range of 17% and 17.5%, up from the previous range of 15.5% to 17%.
Gross profit margin: Pro forma gross profit margin for 2025 is now expected to be within a range of 67% and 67.5% of revenue, an increase from the prior range of 66% to 67%. This reflects greater leverage of fixed costs, benefits from cost reductions, and a lower expected tariff impact for the year.
Tariff impact: The impact of tariffs for 2025 is now expected to be 70 basis points, plus or minus 10 basis points.
Operating expense growth: Pro forma operating expense growth for 2025 is estimated to be between 11% and 13%, including increased depreciation from new facilities and investments to drive growth objectives.
Noncash stock compensation expense: Estimated to be between $785 million and $795 million for 2025.
Other income: Forecasted to total between $350 million and $360 million, mostly comprised of interest income.
Capital expenditures: Expected to range between $625 million and $675 million, reflecting planned facility construction activities.
Income tax rate: Pro forma income tax rate for 2025 is now estimated to be between 21% and 22%, primarily due to the lower Q3 non-GAAP effective tax rate.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: During the quarter, Intuitive used $1.9 billion of cash to repurchase approximately 4 million of its shares. This was part of their capital allocation priorities.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What trends are driving the 20% procedure volume growth year-over-year and quarter-over-quarter, and how sustainable is it?
A:The U.S. da Vinci procedure growth was 13% in Q1, 14% in Q2, and 16% in Q3, showing strong growth in after-hours surgery, acute care, and benign general surgery procedures like cholecystectomy and appendectomy. There was also unexpected growth in hernia repair and benign gynecological procedures. Anecdotal evidence suggests an acceleration of elective procedures in July and August due to Medicare funding and ACA premium changes, though third-party data does not confirm this. Outside the U.S., growth benefited by 1 percentage point due to the timing of holidays in Asia.
Q:How has the introduction of da Vinci 5 impacted procedure growth?
A:The da Vinci 5 was designed to be easier to learn, use, and support higher efficiencies. Data from customers adopting da Vinci 5 supports this design intent. In Q3, 67,000 da Vinci 5 procedures were performed, compared to 50,000 in Q2.
Q:What is the progress and potential of refurbished Xi systems?
A:Refurbished Xi systems are part of the portfolio to meet customer needs, especially for cost-sensitive sites in the U.S. and outside. 20 refurbished Xi systems have been sold so far. The pricing range is not yet disclosed, but it provides flexibility for customers.
Q:How are hospitals utilizing older Xi systems when upgrading to da Vinci 5?
A:Hospitals redeploy older Xi systems to alternative sites of care, such as ASCs, while keeping da Vinci 5 in flagship hospitals. The consistent user interface and interchangeable inventory of instruments between Xi and da Vinci 5 allow seamless operation across platforms.
Q:What are the new platforms and disease states being targeted by Intuitive?
A:Intuitive is focusing on cardiac surgery with da Vinci 5, leveraging its precision, motion control, and imaging integration. They are also exploring unmet healthcare needs where their robotic platforms, advanced imaging, and AI capabilities can make a difference.
Q:What is the outlook for U.S. utilization and net placements of da Vinci systems?
A:Procedure growth is the primary metric of success. The focus is on aligning with customer needs, whether through expanding the installed base or upgrading to da Vinci 5. Long-term U.S. utilization growth will depend on customer segments, with larger institutions likely driving improvements.
Q:What are the factors affecting gross margins and the impact of going direct in certain markets?
A:The Q4 gross margin midpoint is slightly below 67%. The outlook for next year will be provided in January. Going direct in Italy, Spain, and Portugal is expected to be slightly accretive to pro forma EPS by eliminating distributor margins.
Q:What are the challenges and outlook for bariatric procedures and the China market?
A:Domestic bariatric procedures have been declining for six quarters due to the impact of GLP-1 drugs. Surgeons are not yet predicting when declines will end. In China, the environment remains constrained and competitive, with slow tenders and price pressure on capital and I&A.
Q:What is the role of the Hub and digital tools in enhancing da Vinci 5 performance?
A:The Hub collects video data for analysis, enabling insights through AI and machine learning. This digital foundation supports augmented dexterity and intraoperative guidance, helping surgeons make better decisions to optimize outcomes and economics.
Q:What is the potential for da Vinci systems in alternative sites of care like ASCs?
A:The primary constraint is capital cost, with many systems in ASCs being leased. Reimbursement in ASCs is lower than in HOPDs, but I&A prices have not been a major issue. Sterilization has not been an impediment, and single-use I&A is not required.
Q:What is the progress and outlook for SP and Ion systems?
A:SP systems are growing, with 92% procedure growth and high utilization in Korea. Clearances in the U.S. are being expanded. Ion systems also show strong growth, with over 50% procedure growth.
Q:What is the feedback and rollout strategy for da Vinci 5 in Europe and Japan?
A:The rollout is focused on larger institutions that want to adopt the latest technology. There is some cost sensitivity compared to the U.S. market, and customers are working through the evaluation process.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the pricing range for refurbished Xi systems, the long-term outlook for gross margins, and the timeline for when bariatric procedure declines might end. Additionally, they did not elaborate on the specific unmet healthcare needs being targeted by new platforms or provide detailed insights into the impact of going direct in certain markets.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Brazil
CT
China UK
FDA clearance
IA procedure
Italy
Japan China
Japan Europe
Korea Taiwan
Quintuple Aim
SP stapler
Technology
analysis
base utilization
capital placement
console system
demand system
efficiency
forma share
geography
imaging
integration
intent
navigation
platform procedure
procedure IA
procedure SP
release tax
site care
surgeon autonomy
system Japan
system mix
tax reform
tax reserve
thoracic procedure
today program
update
upgrade
utilization market
utilization procedure
ISRG Transcript
Cathay General Bancorp (CATY) Q4 2025 Earnings Call Transcript
Positive1-22
The earnings call reflects positive financial performance with increased net income, EPS, and deposit growth. The guidance adjustments for da Vinci procedures and gross profit margin are optimistic, and the Q&A indicates rational market competition. Despite some concerns about special mention loans, the overall sentiment is positive, with management providing clear responses. The positive factors outweigh negatives, suggesting a likely stock price increase within 2% to 8% over the next two weeks.
Intuitive Surgical, Inc. (ISRG) Q4 2025 Earnings Call Transcript
Positive1-22
The earnings call summary indicates positive developments: increased guidance for da Vinci procedures and gross profit margins, a strategic focus on expanding minimally invasive cardiac procedures, and leveraging advanced imaging and ASC opportunities. Despite competitive pressures in China, the company is adapting well, with promising SP system growth and new digital offerings. While management avoided specific 2026 projections, the overall sentiment remains optimistic, supported by procedure growth and strategic initiatives. The absence of market cap data limits precise prediction, but the positive guidance and strategic direction suggest a positive stock reaction.
Intuitive Surgical, Inc. (ISRG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Intuitive Surgical, Inc. (ISRG) Q3 2025 Earnings Call Transcript
Positive10-21
The earnings call highlights strong growth in procedure volumes and successful adoption of the da Vinci 5 system, indicating positive market reception. Despite challenges in the bariatric and China markets, guidance updates reflect strategic adaptability. The Q&A section provides additional insights into growth areas like alternative care sites and new platforms, supporting a positive outlook. However, management's lack of clarity on certain issues tempers the sentiment slightly. Overall, the combination of strong financial performance, strategic initiatives, and positive guidance adjustments suggests a positive stock price movement.
ISRG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
